

ForPatients

by Roche

Advanced Prostate Cancer Metastatic Prostate Cancer

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

Trial Status
Recruiting

Trial Runs In
7 Countries

Trial Identifier
NCT05800665 2023-504013-68-00
GO44537

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or metastatic prostate cancer. It will also identify recommended doses and regimens for RO7656594 for subsequent studies.

Genentech, Inc.
Sponsor

Phase 1
Phase

NCT05800665 2023-504013-68-00 GO44537
Trial Identifiers

Eligibility Criteria:

Gender
Male

Age
≥18 Years

Healthy Volunteers
No
